Intrexon (NYSE:XON)‘s stock had its “buy” rating restated by equities research analysts at Northland Securities in a research report issued on Friday. They currently have a $17.00 price objective on the biotechnology company’s stock. Northland Securities’ price target points to a potential upside of 5.66% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. ValuEngine lowered Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Stifel Nicolaus increased their price target on Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Bank of America decreased their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Finally, Zacks Investment Research upgraded Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $37.50.

Intrexon (NYSE XON) opened at $16.09 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85. Intrexon has a 1 year low of $10.26 and a 1 year high of $26.99. The firm has a market capitalization of $1,664.95, a price-to-earnings ratio of -16.42 and a beta of 1.30.

Intrexon (NYSE:XON) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.08. Intrexon had a negative return on equity of 16.85% and a negative net margin of 50.61%. The business had revenue of $77.03 million during the quarter, compared to analyst estimates of $48.16 million. During the same quarter last year, the company posted ($0.37) EPS. Intrexon’s revenue for the quarter was up 67.5% on a year-over-year basis. research analysts expect that Intrexon will post -0.87 earnings per share for the current fiscal year.

In other Intrexon news, CEO Randal J. Kirk acquired 1,000,000 shares of Intrexon stock in a transaction that occurred on Friday, January 19th. The stock was purchased at an average cost of $12.50 per share, with a total value of $12,500,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 55.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC purchased a new stake in Intrexon in the 3rd quarter worth about $121,000. SG Americas Securities LLC purchased a new stake in Intrexon in the 3rd quarter worth about $139,000. Quantbot Technologies LP lifted its stake in Intrexon by 423.7% in the 3rd quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 8,085 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in Intrexon in the 4th quarter worth about $124,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in Intrexon in the 4th quarter worth about $138,000. 74.86% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Northland Securities Reiterates “Buy” Rating for Intrexon (XON)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.